Detection of CTNNB1 mutations involves genetic testing of tumor samples. Techniques such as next-generation sequencing and polymerase chain reaction (PCR) are commonly used to identify mutations in clinical settings. Early detection of these mutations can help tailor personalized treatment plans for patients, potentially improving outcomes.
